

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
THE PROGRESS OF PROPOSED ISSUE OF A SHARES

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

References are made to the Company’s announcements dated October 14, 2019, January 22, 2020, February 3, 2020, March 19, 2020, April 14, 2020, April 21, 2020, and May 4, 2020, circular dated October 14, 2019 and supplemental circular dated November 14, 2019 containing, among other things, related matters of the proposed initial public issue of A Shares (the “**Proposed Issue of A Shares**”) and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange.

The Company has submitted the Response to the Opinion Implementation Letter of the Listing Committee of Sci-tech Innovation Board for the Initial Public Offering and Listing on the Sci-Tech Innovation Board of CanSino Biologics Inc. (the “**Response**”) to the Shanghai Stock Exchange. The Response has been published on the website of the Review and Approval of the Issuance and Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange (上交所科創板股票發行上市審核網站) at kcb.sse.com.cn.

As the Proposed Issue of A Shares is subject to certain conditions precedent, it may or may not be completed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the H shares of the Company. Further announcement(s) regarding the details and developments of the Proposed Issue of A Shares will be made by the Company as and when appropriate. This announcement appears for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.

By Order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, May 8, 2020

As at the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.